Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. furnished an investor presentation as part of a corporate update. On September 8, 2025, the company made a “Corporate Presentation” available in the investor relations section of its website and attached it as Exhibit 99.1. Management may use this presentation in future meetings to discuss the company. The materials include a slide on forward-looking statements that outlines important cautionary information. The presentation and related information are furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma reported a period of transition as it pivots ABP-450 development toward a biosimilar pathway after discontinuing Phase 2 migraine trials in May 2024. The company completed a 1-for-72 reverse stock split and raised net proceeds of approximately $18.3 million from a January 2025 public offering and has an ATM program with about $49.8 million remaining. As of June 30, 2025, AEON held $8.4 million in cash and total assets of $11.7 million, against total liabilities of $27.5 million, resulting in a stockholders' deficit of $15.9 million. The company recorded a $75.6 million non‑cash loss on warrant issuance and recognized fair value movements on convertible notes and contingent consideration that materially affected reported (loss) income. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing will be required to advance analytical studies, a planned FDA BPD Type 2a meeting and further development of ABP-450.
AEON Biopharma, Inc. furnished an update on its business by announcing financial results for the second quarter ended June 30, 2025. The company disclosed that these results were communicated through a press release dated August 12, 2025, which is included as Exhibit 99.1 to this Form 8-K.
The press release is treated as "furnished" rather than "filed" under the securities laws, which means it is not automatically subject to certain liability provisions and is not incorporated into other filings unless specifically referenced. No detailed financial figures are included in this report itself; those appear in the accompanying press release.